

Technology Advisory Committee A Interests Register

Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma [ID4030]

Publication Date: 29th August 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Patrick De Barr	Committee A Member	Direct – financial interests	The company Patrick works for has a PD1 antibody at late stage development but in a different indication. This has been declared at previous meetings.	12/03/2024	It was agreed that Patrick's declaration would not prevent him from being part of the committee.
			Patrick received paid employment from a company who have a PD1 antibody under development, however this is in a different indication.	25/01/2024	